Can Kratom or 7-OH Affect Your Lungs? Breathing Risks

What Are Orphines?

"Orphines" is an informal term used for an emerging group of novel synthetic opioids. DEA describes cychlorphine, spirochlorphine, 5,6-dichloro brorphine, and 5,6-dichloro desmethylchlorphine as novel synthetic opioids belonging to a class colloquially known as orphines. Although these drugs are only recently appearing in illicit drug markets, their chemistry has older roots. DEA notes that compounds in this general family, including benzimidazolinyl piperidine derivatives, appeared in pharmaceutical research dating to a U.S. patent from 1967. More recently, related substances have moved from experimental chemistry into the recreational drug supply. The Center for Forensic Science Research and Education, or CFSRE, reports that orphine analogues began appearing more prominently in recreational markets following the emergence of brorphine around 2020. Unlike prescription opioids developed and approved for medical treatment, the four substances DEA scheduled in August 2026 have no currently accepted medical use in the United States.

Which Orphines Did DEA Schedule?

DEA’s August 27, 2026 temporary scheduling order covers four synthetic opioids:

• N-propionitrile chlorphine, commonly called cychlorphine
• Spirochlorphine, also known as R-6890
• 5,6-dichloro brorphine, also known as SR-14968
• 5,6-dichloro desmethylchlorphine, also known as SR-17018

DEA temporarily placed all four in Schedule I after evaluating their history and pattern of abuse, scope of abuse, and risks to public health. The order became effective August 27, 2026 and is scheduled to remain in effect through August 27, 2028 unless extended or replaced through the permanent scheduling process. This is important because emergency Schedule I placement is not routine. DEA specifically concluded that temporary control was necessary to address an imminent hazard to public safety.

What Is Cychlorphine?

Cychlorphine is one of the best-documented members of this emerging group. Its technical name is N-propionitrile chlorphine. Cychlorphine is a synthetic opioid with activity at opioid receptors, and early laboratory research suggests it may be exceptionally potent. CFSRE reports in vitro pharmacology data indicating that cychlorphine may be approximately 10 times more potent than fentanyl. That comparison requires context. Laboratory potency does not mean that every real-world cychlorphine exposure is exactly ten times as dangerous as every fentanyl exposure. Street-drug potency depends on concentration, dose, formulation, other substances present, individual tolerance, and many other factors. What the laboratory finding does indicate is that cychlorphine is not a minor or weak opioid. Extremely small differences in dose may matter. CFSRE first detected cychlorphine in its laboratory in mid-2024. Fatal-overdose detections increased substantially during late 2025 and early 2026.

Why Cychlorphine Can Be Difficult to Detect

One of the greatest challenges involving novel synthetic opioids is that laboratory testing often lags behind the illicit drug market. Routine drug screens are designed to detect substances clinicians and laboratories already expect to encounter. A completely new synthetic opioid may not appear on a standard test. Cychlorphine illustrates that problem particularly well. CFSRE and other forensic laboratories have emphasized the need for advanced analytical techniques to identify emerging opioids. A 2026 case report involving a patient treated for an apparent opioid overdose required comprehensive toxicological analysis before cychlorphine was identified. The patient reportedly believed she had taken alprazolam. Instead, she developed unresponsiveness and respiratory depression and received 6 mg of intranasal naloxone before arriving at the emergency department. Specialized testing later confirmed cychlorphine along with several other substances. This illustrates a central danger of today’s drug supply: People may not know they are taking an opioid at all.

What Is Spirochlorphine?

Spirochlorphine, also known as R-6890, is another synthetic opioid included in DEA’s August 2026 scheduling action. Its chemical history predates its recent appearance in recreational drug markets. CFSRE describes spirochlorphine as part of the broader history of compounds that eventually contributed to today’s orphine analogue class. Recent forensic monitoring has identified spirochlorphine in toxicology cases, including cases where cychlorphine and other new psychoactive substances were also present. CFSRE’s early surveillance data identified presumptive spirochlorphine-positive cases among samples examined from 2024 through 2025. The important point for consumers is not memorizing every chemical name. It is understanding that the illicit opioid supply continues developing new analogues faster than most people can reasonably track. Someone attempting to purchase fentanyl, heroin, or another familiar substance may have little way of knowing whether a newer synthetic opioid is also present.

What Are 5,6-Dichloro Brorphine and SR-17018?

The other two opioids included in DEA’s August order are 5,6-dichloro brorphine, sometimes called SR-14968, and 5,6-dichloro desmethylchlorphine, also known as SR-17018. Like cychlorphine and spirochlorphine, these substances belong to the emerging synthetic opioid group commonly described as orphines. DEA reports that recreational drug discussions involving these compounds have compared their effects with established opioids such as fentanyl and morphine. The agency also notes that forensic drug exhibits and toxicology samples indicate these substances are being trafficked and abused in ways similar to other synthetic opioids. DEA concluded that all four substances warranted emergency Schedule I control because of the risks they pose to public health.

Why Are New Synthetic Opioids Appearing So Quickly?

The illicit drug supply is constantly changing. When governments restrict one group of psychoactive compounds, clandestine manufacturers may alter molecular structures or introduce different substances. This has happened repeatedly. Fentanyl analogues expanded dramatically during earlier stages of the opioid epidemic. Nitazenes later emerged as another group of highly potent synthetic opioids. Now orphine analogues are appearing more frequently in forensic toxicology and illicit drug samples. CFSRE reported that following China’s July 2025 generic controls on nitazene analogues, nitazene positivity decreased while orphine positivity increased, driven substantially by cychlorphine. That does not prove one drug class simply replaced another. It does demonstrate how quickly illicit drug markets can adapt.

Orphines vs. Fentanyl vs. Nitazenes

Orphines, fentanyl, and nitazenes are all synthetic opioids, but they are not the same drug family.

The practical concern is not determining which family is "worst." It is that the illicit opioid supply now contains multiple classes of highly potent synthetic opioids, sometimes in the same sample. A person may believe they are using fentanyl while actually being exposed to fentanyl plus cychlorphine, a nitazene, a sedative, or another unexpected substance.

Are Orphines Stronger Than Fentanyl?

There is not enough evidence to accurately rank every orphine against fentanyl using one simple number. The clearest potency concern currently involves cychlorphine. CFSRE has cited in vitro evidence suggesting cychlorphine may be approximately ten times more potent than fentanyl, and the 2026 Tennessee wastewater study similarly characterized it as a highly potent synthetic opioid. However, laboratory receptor potency does not translate directly into a predictable human dose. Real-world overdose risk depends on many variables. What matters clinically is that orphines can have powerful opioid effects and may appear in an unpredictable illicit drug supply.

Orphines Are Often Part of Polysubstance Overdoses

Cychlorphine has repeatedly appeared alongside other drugs. In CFSRE’s initial series of 25 fatal overdose specimens, cychlorphine was the only identified opioid in 11 cases. Other cases included fentanyl and related opioids, methamphetamine, cocaine, benzodiazepine-type novel psychoactive substances, nitazene analogues, carfentanil, and other orphine analogues. Tennessee data tell a similar story. The East Tennessee overdose deaths described in the 2026 wastewater study frequently involved substances such as fentanyl, phenazolam, and xylazine. This makes it difficult to think about cychlorphine as an isolated drug. It is better understood as part of an increasingly complex polysubstance environment.

Can Someone Become Addicted to Cychlorphine or Other Orphines?

DEA’s scheduling action reflects significant concern about abuse potential. These drugs activate opioid systems associated with reinforcement, tolerance, dependence, and compulsive use. Repeated opioid exposure can cause the brain and body to adapt. Over time, someone may need opioids simply to avoid withdrawal or feel normal. The specific withdrawal characteristics of every newly emerging orphine have not been comprehensively studied in humans. That uncertainty is another reason clinicians should evaluate the person’s overall opioid-use pattern rather than attempting to base treatment solely on the name of a novel drug. If someone believes they have been using fentanyl but has actually been exposed to fentanyl plus cychlorphine or another potent synthetic opioid, they may still present with opioid dependence and withdrawal requiring professional evaluation.

What Does Synthetic Opioid Withdrawal Feel Like?

Opioid withdrawal commonly involves intense physical and psychological discomfort. People may experience anxiety, restlessness, sweating, muscle and joint discomfort, gastrointestinal symptoms, insomnia, chills, cravings, agitation, and depressed mood. Withdrawal experiences differ according to the opioids involved, frequency and duration of use, tolerance, other substances, medical history, and individual physiology. With emerging opioids, there may also be uncertainty about exactly what a person has been taking. This is why trying to identify a drug based solely on appearance or street name is unreliable.

Why Nashville Should Pay Attention Even Though the Early Cluster Was in East Tennessee

The largest documented Tennessee cychlorphine cluster has been concentrated in the eastern portion of the state. That does not mean Middle Tennessee is insulated from emerging synthetic opioids. The illicit drug supply moves across cities, counties, and state lines. CFSRE has already identified cychlorphine-containing specimens from multiple U.S. states and Canadian provinces, while specialized laboratories continue reporting wider detection. The most clearly documented Tennessee cluster has been in East Tennessee, so it would be inaccurate to imply that Nashville is currently experiencing the same concentration of cychlorphine cases. But Nashville does not need a confirmed local cluster for the information to matter. CFSRE has identified cychlorphine-positive specimens from multiple U.S. states and Canadian provinces, demonstrating that the drug is not confined to one Tennessee region. For treatment providers, emergency departments, first responders, families, and people using opioids, the appropriate response is awareness rather than panic. People do not need to memorize each newly emerging opioid. They need to understand that today’s illicit drug supply can contain substances that are more potent, less familiar, and harder to identify than expected.

Why Polysubstance Use Changes Detox Planning

Emerging opioids are frequently found with other substances. Someone entering treatment may have recently used opioids along with alcohol, benzodiazepines, stimulants, xylazine, or other drugs. That matters because withdrawal from different substances carries different risks. For example, opioid withdrawal can be extremely uncomfortable and can contribute to rapid relapse and overdose. Alcohol detox and benzodiazepine detox may require especially careful medical planning because withdrawal from these substances can create potentially life-threatening complications in some people. A thorough assessment therefore considers the entire substance-use history. Treating only the drug someone believes they were using can miss important medical risks.

Detox Is Only the First Step

Medical stabilization is important, but opioid recovery does not end when withdrawal improves. People often benefit from continuing addiction treatment that addresses cravings, relapse prevention, mental health, relationships, trauma, coping skills, and the circumstances that contributed to substance use. Live Again Detox offers continuing addiction-treatment options in Nashville following stabilization, including residential treatment and structured behavioral-health services when clinically appropriate. For people living with both addiction and depression, anxiety, trauma, PTSD, or another mental health concern, dual diagnosis treatment can address substance use and mental health together. This becomes particularly important when opioids have been used as a way to cope with emotional distress.

What Are the Signs of a Synthetic Opioid Overdose?

A person exposed to cychlorphine or another potent synthetic opioid may show the same life-threatening signs seen with other opioid overdoses. Warning signs can include:

• inability to wake up,
• very slow, irregular, or stopped breathing,
• blue, gray, or pale lips or fingertips,
• pinpoint pupils,
• limpness,
• choking, snoring, or gurgling sounds, and
• severe sedation or loss of consciousness.

Because people may not know which opioid they were exposed to, overdose response should be based on symptoms rather than waiting for a specific drug identification.

What Tennessee Families Should Know About the New Orphines

The emergence of cychlorphine does not mean families need to learn an endless list of chemical names. The larger lesson is more important. The illicit opioid supply is changing rapidly. A substance sold as fentanyl, heroin, or a counterfeit prescription pill may contain unfamiliar synthetic opioids that are difficult to detect and potentially extremely potent. DEA’s August 27, 2026 emergency scheduling action shows that federal officials view this new group of synthetic opioids as a serious enough threat to warrant immediate control. Tennessee’s experience with cychlorphine shows why that concern matters locally. For anyone using illicit opioids, the safest option is to seek treatment before another exposure occurs.